These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 28396197)
1. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells. Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197 [TBL] [Abstract][Full Text] [Related]
2. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors. Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516 [TBL] [Abstract][Full Text] [Related]
3. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy. Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878 [TBL] [Abstract][Full Text] [Related]
4. New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. Cepa M; Correia-da-Silva G; da Silva EJ; Roleira FM; Borges M; Teixeira NA BMC Cell Biol; 2008 Jul; 9():41. PubMed ID: 18652661 [TBL] [Abstract][Full Text] [Related]
5. Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis. Amaral C; Varela C; Borges M; Tavares da Silva E; Roleira FMF; Correia-da-Silva G; Teixeira N Apoptosis; 2013 Nov; 18(11):1426-1436. PubMed ID: 23842740 [TBL] [Abstract][Full Text] [Related]
6. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847 [TBL] [Abstract][Full Text] [Related]
7. Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line. Varela CL; Amaral C; Tavares da Silva E; Lopes A; Correia-da-Silva G; Carvalho RA; Costa SC; Roleira FM; Teixeira N Eur J Med Chem; 2014 Nov; 87():336-45. PubMed ID: 25277066 [TBL] [Abstract][Full Text] [Related]
8. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755 [TBL] [Abstract][Full Text] [Related]
9. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684 [TBL] [Abstract][Full Text] [Related]
10. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells. Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846 [TBL] [Abstract][Full Text] [Related]
11. Exploring new chemical functionalities to improve aromatase inhibition of steroids. Varela CL; Amaral C; Correia-da-Silva G; Costa SC; Carvalho RA; Costa G; Alcaro S; Teixeira NA; Tavares-da-Silva EJ; Roleira FM Bioorg Med Chem; 2016 Jun; 24(12):2823-31. PubMed ID: 27160054 [TBL] [Abstract][Full Text] [Related]
12. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications. Hanamura T; Hayashi SI Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808 [TBL] [Abstract][Full Text] [Related]
13. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane. Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807 [TBL] [Abstract][Full Text] [Related]
14. Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane. Amaral C; Lopes A; Varela CL; da Silva ET; Roleira FM; Correia-da-Silva G; Teixeira N Int J Biochem Cell Biol; 2015 Dec; 69():183-95. PubMed ID: 26515125 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887 [TBL] [Abstract][Full Text] [Related]
16. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468 [TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. Kijima I; Itoh T; Chen S J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]